Julie M Gastier-Foster
Overview
Explore the profile of Julie M Gastier-Foster including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
7518
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Velu P, Cushman-Vokoun A, Ewalt M, Feilotter H, Gastier-Foster J, Goswami R, et al.
J Mol Diagn
. 2022 Jun;
24(8):825-840.
PMID: 35690309
In the two decades since Accreditation Council for Graduate Medical Education-accredited Molecular Genetic Pathology fellowships began, the field of clinical molecular pathology has evolved considerably. The American Board of Pathology...
12.
Lyon E, Temple-Smolkin R, Hegde M, Gastier-Foster J, Palomaki G, Richards C
J Mol Diagn
. 2022 Apr;
24(6):555-565.
PMID: 35429647
The Association for Molecular Pathology Variant Interpretation Testing Among Laboratories (VITAL) Working Group convened to evaluate the Standards and Guidelines for the Interpretation of Sequence Variants implementation into clinical practice,...
13.
Burke M, Devidas M, Chen Z, Salzer W, Raetz E, Rabin K, et al.
Leukemia
. 2021 Nov;
36(3):648-655.
PMID: 34725453
Adolescent and young adult (AYA) patients 16-30 years old with high-risk acute lymphoblastic leukemia (HR-ALL) have inferior outcomes compared to younger HR-ALL patients. AALL0232 was a Phase 3 randomized Children's...
14.
Irwin M, Naranjo A, Zhang F, Cohn S, London W, Gastier-Foster J, et al.
J Clin Oncol
. 2021 Jul;
39(29):3229-3241.
PMID: 34319759
Purpose: Treatment planning for children with neuroblastoma requires accurate assessment of prognosis. The most recent Children's Oncology Group (COG) risk classification system used tumor stage as defined by the International...
15.
Li Y, Yang W, Devidas M, Winter S, Kesserwan C, Yang W, et al.
J Clin Invest
. 2021 Jun;
PMID: 34166225
Genetic alterations in the RUNX1 gene are associated with benign and malignant blood disorders, particularly of megakaryocyte and myeloid lineages. The role of RUNX1 in acute lymphoblastic leukemia (ALL) is...
16.
Morton L, Karyadi D, Stewart C, Bogdanova T, Dawson E, Steinberg M, et al.
Science
. 2021 Apr;
372(6543).
PMID: 33888599
The 1986 Chernobyl nuclear power plant accident increased papillary thyroid carcinoma (PTC) incidence in surrounding regions, particularly for radioactive iodine (I)-exposed children. We analyzed genomic, transcriptomic, and epigenomic characteristics of...
17.
Granger M, Naranjo A, Bagatell R, Dubois S, McCune J, Tenney S, et al.
Transplant Cell Ther
. 2021 Apr;
27(6):490.e1-490.e8.
PMID: 33823167
Consolidation using high-dose chemotherapy with autologous stem cell transplantation (ASCT) is an important component of frontline therapy for children with high-risk neuroblastoma. The optimal preparative regimen is uncertain, although recent...
18.
Oshima K, Zhao J, Perez-Duran P, Brown J, Patino-Galindo J, Chu T, et al.
Nat Cancer
. 2021 Apr;
1(11):1113-1127.
PMID: 33796864
Multi-agent combination chemotherapy can be curative in acute lymphoblastic leukemia (ALL). Still, patients with primary refractory disease or with relapsed leukemia have a very poor prognosis. Here we integrate an...
19.
Mattano Jr L, Devidas M, Maloney K, Wang C, Friedmann A, Buckley P, et al.
J Clin Oncol
. 2021 Mar;
39(14):1540-1552.
PMID: 33739852
Purpose: Children's Oncology Group (COG) AALL0331 tested whether pegaspargase intensification on a low-intensity chemotherapy backbone would improve the continuous complete remission (CCR) rate in a low-risk subset of children with...
20.
Kawano A, Hazard F, Chiu B, Naranjo A, LaBarre B, London W, et al.
Am J Surg Pathol
. 2021 Mar;
45(8):1075-1081.
PMID: 33739795
Stage 4S neuroblastoma (4SNB) is associated with spontaneous tumor regression and an excellent prognosis. However, a small group of the patients have a poor prognosis. One hundred eighty-five stage 4SNB...